Advertisement
Organisation › Details
Imperial Innovations (Group)
Imperial Innovations Group plc creates, builds and invests in pioneering technologies developed from the academic research within the ‘Golden Triangle’ broadly bounded by London, Cambridge and Oxford, which is home to the UK’s four leading research-intensive universities. This area is home to many new technology companies through its proximity to the academic communities of Imperial College London, the University of Cambridge, the University of Oxford and University College London, as well as other leading research institutions. Imperial College London, the University of Cambridge, the University of Oxford and University College London collectively have research income of £1.4 billion per annum and are ranked as four of the top ten Universities in the world (source: QS World University Rankings 2014/15). Innovations supports scientists and entrepreneurs in the commercialisation of their ideas through the licensing of intellectual property, by leading the formation of new companies, providing facilities in the early stages, providing investment and encouraging co-investment to accelerate development, providing operational expertise and recruiting high-calibre management teams. It also runs an incubator in London that is the initial home for many of its technology spin-outs. Since admission of its shares to trading on AIM in 2006, Innovations has raised more than £346.0 million of equity from investors, which has enabled it to invest in some of the most exciting spin-outs to come out of UK academic research. In addition, the Group has a £30.0 million loan facility from the European Investment Bank (EIB) for investment in biotech and therapeutics businesses. During the period from admission on AIM up until 31 July 2014, Innovations has invested a total of £176.0 million across its portfolio companies, which have raised collectively investment of £822.5 million. *
End | 2017-01-01 | |
Group | IP Group (Group) | |
Today | IP Group (Group) | |
Successor | Touchstone Innovations (Group) | |
Industry | IP services | |
Industry 2 | venture capital | |
Person | Searle, Susan (Imperial Innovation 200511 CEO) | |
Person 2 | Pitchford, Nigel (Downing 202302 Head of Healthcare Ventures formerly Imperial Innovations before 3i) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 52 Princes Gate Exhibition Road | |
City | SW7 2PG London | |
Tel | +44-20-7581-4949 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2022-05-22 |
Advertisement
More documents for IP Group (Group)
- [1] Elsamogen Ltd.. (5/18/22). "Press Release: BGF, Scottish National Investment Bank and Scottish Enterprise Join Forces to Invest £8m in Aberdeen Biologics Company Elasmogen". Aberdeen....
- [2] Semarion Ltd.. (2/22/22). "Press Release: Semarion Raises £2.14m Seed Funding to Commercialise Cell Assaying Platform". Cambridge....
- [3] Boehringer Ingelheim. (10/19/21). "Press Release: Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis". Paris....
- [4] IP Group plc. (5/4/21). "Press Release: Portfolio Company Oxford Nanopore Technologies Raises £195m in New Investment"....
- [5] Mogrify Ltd.. (5/4/21). "Press Release: Mogrify Completes Series A financing Totaling $33 Million USD". Cambridge....
- [6] CytoSeek Ltd.. (3/16/21). "Press Release: CytoSeek Raises £3.57M ($5M) to Advance Its Mission to Develop the Next Generation of Cell Therapies for Cancer". Bristol....
- [7] PredictImmune Ltd.. (7/30/19). "Press Release: PredictImmune Closes Series B Funding Round, Raising £10M to Further Accelerate Global Commercial Expansion and Support Expanding Product Pipeline". Cambridge....
- [8] Genomics plc. (8/30/18). "Press Release: Genomics plc Raises £25 million in Series B Round to Advance Its Use of Human Genetics and Data Science in Drug Discovery". Oxford....
- [9] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...
- [10] IP Group plc. (5/15/18). "Press Release: IP Group and Johns Hopkins Collaboration Funds Cancer Therapeutic Start-up"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top